Timing is Everything: Early Chemotherapy Boosts Colorectal Cancer Survival
Study finds starting chemotherapy within 6 weeks after colorectal cancer surgery improves survival rates.
Gynecologic Cancers
9 articles
Gut Microbiome: A New Frontier in Predicting Immunotherapy Outcomes for Gynecologic Cancers
Study reveals gut bacteria's role in immunotherapy outcomes for cervical and endometrial cancer patients.
Cediranib/Olaparib Combo Falls Short in Platinum-Resistant Ovarian Cancer Trial
Phase II/III trial shows cediranib/olaparib not superior to chemotherapy in platinum-resistant ovarian cancer.
Immunotherapy Breakthrough: Pembrolizumab Boosts Survival in Advanced Cervical Cancer
Pembrolizumab plus chemoradiotherapy significantly improves survival in high-risk cervical cancer patients.
Rucaparib's Promise: New Hope for Recurrent Ovarian Cancer Patients
Meta-analysis reveals rucaparib's efficacy in treating recurrent ovarian cancer, especially in BRCA carriers.
Combo Therapy Shows Promise in Advanced Endometrial Cancer Trial
Phase 2 trial evaluates PARP inhibitor and antiangiogenic agent in recurrent endometrial cancer.
New Strategies Explored: Immune Checkpoint Inhibitors in Ovarian Cancer
Study compares sequential vs. combination immunotherapy in platinum-resistant ovarian cancer patients.
New Drug Combo Falls Short in Ovarian Cancer Trial
Phase III trial of ofranergene obadenovec plus paclitaxel fails to improve outcomes in ovarian cancer
Dual Immunotherapy Boosts Endometrial Cancer Outcomes
Durvalumab plus chemo followed by durvalumab +/- olaparib improves PFS in advanced endometrial cancer
Olaparib Rechallenge Offers Hope for Relapsed Ovarian Cancer Patients
Study shows olaparib rechallenge improves progression-free survival in platinum-sensitive relapsed ovarian cancer